Sionna Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451
Mailing Address
21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451
Phone
617-819-2020
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$61.69M
Net Income
$19.12M
Total Liabilities
$-1.88
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 10-K Annual financial report | March 2, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Lead drug candidate SION-638 is in Phase 2 clinical trials, with initial data anticipated in late 2026, and SION-718 is in Phase 1 development.
- The company held $210 million in cash, cash equivalents, and marketable securities as of December 31, 2025, estimated to fund operations into Q3 2027.
Insider Trading
STRONG SELL
4 insiders
15 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.